CR20130133A - Composiciones de anticuerpo y mètodos de uso - Google Patents
Composiciones de anticuerpo y mètodos de usoInfo
- Publication number
- CR20130133A CR20130133A CR20130133A CR20130133A CR20130133A CR 20130133 A CR20130133 A CR 20130133A CR 20130133 A CR20130133 A CR 20130133A CR 20130133 A CR20130133 A CR 20130133A CR 20130133 A CR20130133 A CR 20130133A
- Authority
- CR
- Costa Rica
- Prior art keywords
- methods
- antibody compositions
- antibody
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/088—Varicella-zoster virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/089—Cytomegalovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38772510P | 2010-09-29 | 2010-09-29 | |
US38773510P | 2010-09-29 | 2010-09-29 | |
US201161504056P | 2011-07-01 | 2011-07-01 | |
PCT/US2011/054092 WO2012047732A2 (en) | 2010-09-29 | 2011-09-29 | Antibody compositions and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20130133A true CR20130133A (es) | 2013-08-29 |
Family
ID=45890018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20130133A CR20130133A (es) | 2010-09-29 | 2013-03-21 | Composiciones de anticuerpo y mètodos de uso |
Country Status (21)
Country | Link |
---|---|
US (2) | US20120082666A1 (es) |
EP (1) | EP2621533A4 (es) |
JP (1) | JP2014501491A (es) |
KR (1) | KR20130112879A (es) |
CN (2) | CN103313727B (es) |
AR (1) | AR083214A1 (es) |
AU (1) | AU2011312425A1 (es) |
BR (1) | BR112013007514A2 (es) |
CA (1) | CA2811087A1 (es) |
CL (1) | CL2013000868A1 (es) |
CO (1) | CO6690799A2 (es) |
CR (1) | CR20130133A (es) |
EA (1) | EA201390467A1 (es) |
EC (1) | ECSP13012536A (es) |
HK (1) | HK1189501A1 (es) |
IL (1) | IL225389A0 (es) |
MA (1) | MA34541B1 (es) |
MX (1) | MX2013002960A (es) |
PE (1) | PE20140195A1 (es) |
SG (1) | SG188657A1 (es) |
WO (1) | WO2012047732A2 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014024023A2 (pt) * | 2012-03-28 | 2017-07-18 | Genentech Inc | anticorpos idiotípicos anti-hcmv e usos dos mesmos |
WO2014099908A1 (en) * | 2012-12-17 | 2014-06-26 | Genentech, Inc. | Methods for inhibiting viral infection in transplant patients |
MX359794B (es) | 2013-03-15 | 2018-10-10 | Intrinsic Lifesciences Llc | Anticuerpos anti-hepcidina y usos de los mismos. |
MX2015016978A (es) * | 2013-06-10 | 2016-04-25 | Merck Sharp & Dohme | Proteinas de union a antigeno neutralizantes de citomegalovirus. |
NZ756749A (en) | 2013-09-13 | 2022-05-27 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
RU2016107435A (ru) | 2013-09-13 | 2017-10-18 | Дженентек, Инк. | Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты |
WO2016049036A1 (en) * | 2014-09-22 | 2016-03-31 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
GB201607979D0 (en) * | 2016-05-06 | 2016-06-22 | Liverpool School Tropical Medicine | Monomeric proteins and uses thereof |
KR20210084535A (ko) * | 2018-10-25 | 2021-07-07 | 케이엠 바이올로직스 가부시키가이샤 | 개변 CMV gB 단백질 및 이것을 포함하는 CMV 백신 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0683675A4 (en) * | 1993-01-28 | 1997-05-21 | Sandoz Pharmaceuticals Corp | HUMAN MONOCLONAL ANTIBODIES AGAINST CYTOMEGALOVIRUS. |
WO1996006625A1 (en) * | 1994-08-26 | 1996-03-07 | Eli Lilly And Company | Antibody constructs with cdr switched variable regions |
US6875433B2 (en) * | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
AU2005295595C1 (en) * | 2004-10-15 | 2012-06-21 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
BRPI0614366A2 (pt) * | 2005-08-11 | 2009-10-06 | Arpi Matossian Rogers | peptìdeo, anticorpo ou fragmento de anticorpo, anticorpo ou ligante funcionalmente equivalente, molécula de ácido nucleico, vetor, célula hospedeira, métodos para expressar um peptìdeo, um anticorpo ou fragmento de anticorpo, um anticorpo ou ligante equivalente e para tratar uma doença em um paciente, composição farmacêutica, composição de vacina, métodos de vacinação de um indivìduo contra uma doença ou um distúrbio e de diagnose de um indivìduo para a presença de anticorpos autoimunes, e, arranjo de peptìdeos |
US20080003605A1 (en) * | 2006-05-24 | 2008-01-03 | The University Of Chicago | Microarray analysis of light chain variable gene expression and methods of use |
CA2654563A1 (en) * | 2006-06-07 | 2007-12-21 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
DK2126049T3 (da) * | 2006-12-15 | 2011-07-18 | Ribovax Biotechnologies Sa | Antistoffer mod humant cytomegalovirus (hCMV) |
PE20141433A1 (es) * | 2008-07-16 | 2014-10-19 | Inst Research In Biomedicine | Anticuerpos neutralizantes de citomegalovirus humano |
-
2011
- 2011-09-29 CN CN201180057119.7A patent/CN103313727B/zh not_active Expired - Fee Related
- 2011-09-29 AU AU2011312425A patent/AU2011312425A1/en not_active Abandoned
- 2011-09-29 KR KR1020137007881A patent/KR20130112879A/ko not_active Application Discontinuation
- 2011-09-29 CA CA2811087A patent/CA2811087A1/en not_active Abandoned
- 2011-09-29 EA EA201390467A patent/EA201390467A1/ru unknown
- 2011-09-29 EP EP11831352.7A patent/EP2621533A4/en not_active Withdrawn
- 2011-09-29 WO PCT/US2011/054092 patent/WO2012047732A2/en active Application Filing
- 2011-09-29 PE PE2013000655A patent/PE20140195A1/es not_active Application Discontinuation
- 2011-09-29 US US13/248,998 patent/US20120082666A1/en not_active Abandoned
- 2011-09-29 CN CN201510363420.0A patent/CN104945505A/zh active Pending
- 2011-09-29 SG SG2013022751A patent/SG188657A1/en unknown
- 2011-09-29 AR ARP110103598A patent/AR083214A1/es not_active Application Discontinuation
- 2011-09-29 MA MA35760A patent/MA34541B1/fr unknown
- 2011-09-29 BR BR112013007514A patent/BR112013007514A2/pt not_active IP Right Cessation
- 2011-09-29 JP JP2013531893A patent/JP2014501491A/ja active Pending
- 2011-09-29 MX MX2013002960A patent/MX2013002960A/es not_active Application Discontinuation
-
2013
- 2013-03-21 IL IL225389A patent/IL225389A0/en unknown
- 2013-03-21 CR CR20130133A patent/CR20130133A/es unknown
- 2013-03-28 CL CL2013000868A patent/CL2013000868A1/es unknown
- 2013-03-28 EC ECSP13012536 patent/ECSP13012536A/es unknown
- 2013-04-12 CO CO13095273A patent/CO6690799A2/es unknown
-
2014
- 2014-03-17 HK HK14102648.6A patent/HK1189501A1/zh not_active IP Right Cessation
- 2014-12-19 US US14/577,991 patent/US20150376265A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CO6690799A2 (es) | 2013-06-17 |
EP2621533A4 (en) | 2015-06-17 |
PE20140195A1 (es) | 2014-02-24 |
JP2014501491A (ja) | 2014-01-23 |
CL2013000868A1 (es) | 2014-01-24 |
IL225389A0 (en) | 2013-06-27 |
MX2013002960A (es) | 2013-05-09 |
US20150376265A1 (en) | 2015-12-31 |
AR083214A1 (es) | 2013-02-06 |
AU2011312425A1 (en) | 2013-04-11 |
CN103313727A (zh) | 2013-09-18 |
BR112013007514A2 (pt) | 2019-09-24 |
SG188657A1 (en) | 2013-05-31 |
KR20130112879A (ko) | 2013-10-14 |
WO2012047732A2 (en) | 2012-04-12 |
WO2012047732A3 (en) | 2013-05-30 |
CA2811087A1 (en) | 2012-04-12 |
US20120082666A1 (en) | 2012-04-05 |
MA34541B1 (fr) | 2013-09-02 |
HK1189501A1 (zh) | 2014-06-13 |
EP2621533A2 (en) | 2013-08-07 |
CN104945505A (zh) | 2015-09-30 |
EA201390467A1 (ru) | 2013-11-29 |
ECSP13012536A (es) | 2013-06-28 |
CN103313727B (zh) | 2015-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO7020870A2 (es) | Anticuerpos anti-htra1 y métodos de uso | |
SMT201500260B (it) | Composti di tioacetato, composizioni e metodi d’uso | |
BR112014028366A2 (pt) | anticorpos anti-ly6e e imunoconjugados e métodos de uso | |
CO6870005A2 (es) | Composición anti-cgrp y uso de las mismas | |
BR112013006016A2 (pt) | compostos de azabenzotiazol, composições e métodos de uso | |
BRPI1012676A2 (pt) | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso | |
BRPI1012560A2 (pt) | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso | |
BR112013014321A2 (pt) | moduladores inovadores e métodos de uso | |
BR112013010988A2 (pt) | composição fluída e uso | |
CL2014002086A1 (es) | Anticuerpos cd47 y métodos de uso los mismos | |
BR112014002716A2 (pt) | anticorpos anti-poliubiquitina e métodos de uso | |
BR112014014547A2 (pt) | compostos antagonistas de e-selectina, composições e métodos de uso | |
CO6870033A2 (es) | Compuestos terapéuticos y métodos de uso relacionados | |
BR112014012590A2 (pt) | anticorpos anti-cd98 e métodos de uso dos mesmos | |
BRPI1014544A8 (pt) | anticorpos anti-il-17f e metodos de uso dos mesmos | |
EP2603237A4 (en) | ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE | |
CO7000773A2 (es) | Composiciones intranasales de dexmedetomidina y métodos de uso de ellas | |
CO7000747A2 (es) | Anticuerpos anti-lrp5 y métodos de uso | |
CL2015001266A1 (es) | Anticuerpos de antihemaglutinina y métodos de uso. | |
CR20130133A (es) | Composiciones de anticuerpo y mètodos de uso | |
BRPI0915928A2 (pt) | composições e métodos de uso para anticorpos terapêuticos | |
CO6930362A2 (es) | Compuesto heterocíclico y su uso | |
BR112012031416A2 (pt) | solução aceleradora e uso de uma solução aceleradora | |
CO6862148A2 (es) | Composiciones transdérmicas de ibuprofeno y métodos de uso de las mismas | |
BR112014009837A2 (pt) | uso eficaz da levedura e extrato de levedura |